
































means	 of	 high	 performance	 liquid	 chromatography	 (HPLC)	 was	 developed	 and	 validated.
Estimated	glomerular	filtration	rate	(eGFR)	has	been	calculated	for	the	patients	with	chronic
kidney	disease	(CKD).	Ion	pair	liquid	chromatography	technique	was	utilized	to	separate	CC
along	 with	 UV	 detection.	 Calibration	 curve	 with	 excellent	 correlation	 (r2	 =	 0.99)	 over	 the
range	 from	0.75	 to	 20.50	mg/L	of	 CC	was	 accomplished.	 Limits	 of	 detection	 and	 quantify‐













Excretion	of	waste	 is	one	of	 the	essential	 functions	of	 the	
kidney.	Any	 interruption	of	the	kidney	results	 in	renal	 failure	
and	 it	 can	 be	 acute	 or	 chronic	 [1].	 In	 case	 of	 renal	 failure	




proteins	 are	 called	 kidney	 failure	 biomarkers	 [2].	 These	 bio‐
markers	 interact	 in	different	manners	 to	 reflect	 the	 situation	
of	 the	 kidney,	 and	 they	 are	 classified	 as	 exogenous	markers,	
such	as:	51Cr‐EDTA,	inulin,	(125I),	iotholamate	(99mTc)	TPA	and	
endogenous	 markers	 such	 as:	 microalbuminuria,	 creatinine,	
cystatins,	 etc.	 [3‐5].	 After	 a	 careful	 review	 of	 each	 marker’s	
properties,	 it	 was	 noticed	 that	 CC	 is	 an	 ideal	 and	 reliable	
marker	 of	 GFR,	 and	 so	 of	 renal	 functions.	 CC	 is	 a	 cysteine	
proteinases	inhibitor.	Large	number	of	pathological	processes	
is	 controlled	 by	 the	 balance	 between	 proteinases	 and	 their	
inhibitors,	 where	 an	 increase	 of	 these	 proteinases	 has	 been	
observed	 in	 case	 of	 inflammation.	 The	 concentration	 of	 CC	
protein	 is	considered	as	an	overall	 index	of	renal	 function.	 In	
case	 of	 GFR	 reduction,	 CC	 leaks	 out	 from	 the	 kidney.	 CC	
amount	in	the	blood	increases	by	two	folds	at	the	early	stages	
of	kidney	failure	[6‐11].	
Different	 immunoassay	 methods	 have	 been	 reported	 for	
determination	of	CC:	Particle	enhanced	nephelometric	 immu‐
neassay	 (PENIA),	 particle	 enhanced	 turbidimetric	 method	
(PET)	 and	 enzyme‐amplified	 single	 radial	 immunediffusion	
[12‐14].	 Due	 to	 the	 interferences	 caused	 by	 antigens‐
antibodies	 cross	 reactions	which	might	 lead	 to	 false	 positive	
results,	long	analysis	time,	in	addition,	to	the	high	coefficient	of	
variation	 obtained	 by	 the	 mentioned	 methods,	 the	 develop‐
ment	 of	 a	 new,	 specific,	 fast	 and	 precise	 method	 is	 deemed	
necessary.	 HPLC‐MS	 analytical	 method	 is	 in	 use	 for	 the	
determination	 of	 CC	 only	 in	 raw	 material	 but	 has	 not	 been	
applied	 to	 biological	 fluids	 [15].	 Another	 HPLC	 method	 has	
been	developed	and	validated	based	on	isotope	dilution	liquid	
chromatography	 principles	 with	 electrospray	 ionization	
detection,	however,	 no	 real	 samples	were	 introduced	 as	well	
[16].	
To	the	best	of	our	knowledge,	there	is	no	chromatographic	
method	 of	 analysis	 has	 been	 developed	 for	 the	 sake	 of	
analyzing	 CC	 in	 human	 blood,	 however,	 a	 method	 has	 been	
developed	and	validated	in	our	previous	work	to	analyze	CC	in	
human	urine	[17,18].	The	present	work	introduces	a	new,	fast,	
economic	 HPLC	 method	 which	 can	 separate,	 detect	 and	
quantify	CC	by	simple	preparation	steps,	 it	 also	conquers	 the	
problems	 of	 the	 previous	 immunoassay	 techniques.	 The	
obtained	 values	 of	 CC	will	 be	 incorporated	 to	 calculate	 eGFR	
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values	 of	 the	 CKD	 patients.	 Based	 on	 the	 calculated	 eGFR	







CC	 protein	 (>96%)	 was	 purchased	 from	 BBI	 Solutions	
(UK),	 HPLC	 grade	 acetonitrile,	 methanol,	 1‐hexane	 sulfonic	





17	 males	 and	 females	 (range	 8‐58	 years	 old)	 of	 healthy	
volunteers	 were	 recruited.	 27	 Males	 and	 females	 patients	
(range	 13‐85	 years	 old)	 with	 known	 history	 of	 renal	 failure	
disease	were	 recruited	 as	well	 from	 hospital	 (Extra	 samples	
from	 the	 medical	 laboratory).	 Implied	 consent	 has	 been	






samples	were	 collected	 in	 heparinized	 tubes	 and	 centrifuged	
at	 (4400	×	 g	 at	 4	 °C)	 for	 5	minutes.	 The	 supernatant	 plasma	
was	 separated	 gently	 by	 a	 dropper	 to	 another	 tube.	 To	
precipitate	 CC;	 2	mL	 of	 plasma	 solution	was	withdrawn	 in	 a	
test	 tube	and	about	8	mL	of	 the	acetone	was	added,	 then	 the	
resulting	 solution	 was	 mixed	 thoroughly	 by	 shaker	 for	 20	
minutes.	After	that,	centrifugation	at	(4400	×	g	at	4	°C)	for	30	
minutes	 took	 place	 and	 the	 resulting	 solid	 precipitate	 was	
dissolved	 in	 4	mL	 0.05%	TFA	 (v:v).	 Finally,	 the	 solution	was	
centrifuged	 at	 (4400	 ×	 g	 at	 4	 °C)	 for	 30	 minutes	 and	 the	





Dionex	HPLC	 system	 (Dionex,	 Germany)	with	 a	 degasser,	
low	pressure	gradient	pump,	column	oven,	an	autosampler,	a	
UV	 detector	 was	 used.	 Data	 acquisition	was	 performed	with	
Chromeleon	7.2	SR2	software.	Another	HPLC	 instrument	was	
used	 to	 perform	 the	 inter‐assay	 (ruggedness)	 test;	 (LC2010	
HPLC	 system,	 Shimadzu,	 Japan),	 Data	 acquisition	 was	
performed	 with	 LC	 Solution	 1.25	 SP2	 Software.	 A	 reversed	




filtered	 through	 0.45	 µm	 teflon	 filter	 and	 mobile	 phase	 B	
(acetonitrile:methanol:mobile	 phase	 A)	 (300:300:225,	 v:v:v),	
pH	=	2.5	filtered	through	0.45	µm	teflon	filter,	were	pumped	at	
a	 flow	 rate	 of	 1.0	 mL/min	 and	 used	 for	 the	 elution	 of	 CC	
utilizing	a	gradient	program.	Before	each	run,	the	column	was	
equilibrated	with	 65%	of	mobile	 phase	 B	 for	 3	minutes.	 The	
gradient	 was	 increased	 gradually	 to	 80%	 in	 3	 minutes	 and	
then	 to	100%	 in	5	minutes	 lasted	2	minutes	 to	 complete	 the	
separation.	 Then,	 the	 gradient	 was	 decreased	 to	 initial	
conditions	65%	in	0.5	minute.	At	14	minutes,	the	HPLC	system	





Validation	 tests	 were	 conducted	 according	 to	 the	 ICH	





To	 build	 up	 the	 calibration	 curve,	 six	 points	 were	
constructed	 from	 CC	 stock	 solution	 (0.2	 mg/mL	 of	 CC	 in	





From	 the	 calibration	 curve	 and	 according	 to	 the	 visual	
evaluation	 method,	 the	 LOD	 is	 defined	 as	 the	 lowest	










of	CC,	high,	medium	and	 low,	 respectively.	 In	order	 to	mimic	
the	exact	environment	of	the	real	sample;	the	final	amount	of	
the	 plasma	 was	 kept	 constant	 in	 all	 levels	 (0.5	 mg/L	 of	 CC)	
during	 the	 dilution	 steps.	 Further	 dilutions	 have	 been	
performed	 from	 the	 lowest	 prepared	 concentration	 (2.50	
mg/L	 of	 CC)	 to	 estimate	 LOD	 and	 LOQ.	 Quality	 control	 (QC)	
samples	 were	 stated	 toward	 the	 beginning	 and	 the	 end	 of	
assay	work	to	determine	the	accuracy	and	the	precision.	RSD’s	
were	determined	from	6	preparations	(inter‐day/ruggedness)	





To	 check	 the	 purity	 of	 the	 peak	 attributed	 to	 CC	 in	 real	











Two	 stability	 study	 approaches	 have	 been	 triggered;	 one	






These	 solutions	 refer	 to	 those	obtained	 after	 applying	 all	
the	 preparation	 steps.	 Stability	 solutions	 were	 prepared	 by	
storing	 prepared	 analytical	 samples	 for	 2	 days	 at	 room	
temperature,	in	the	refrigerator,	and	in	the	freezer	(25	°C,	2	to	
8	°C	and	‐10	to	‐20	°C),	respectively.	The	concentrations	were	





Stability	 solutions	 were	 prepared	 by	 storing	 plasma	
samples	 for	 8	 days	 at	 room	 temperature,	 in	 the	 refrigerator,	
and	 in	 the	 freezer	 (25	 °C,	 2	 to	 8	 °C,	 and	 ‐10	 to	 ‐20	 °C),	
respectively.	 Then	 the	 sample	 preparation	 procedure	 was	







Concentration	(mg/L)	 QC	Sample	 Accuracy	CC	(%)	 %RSD	
10.50	 MAX	 93.6±15 8.4±15	
5.50	 MEDIUM	 98.9±15 6.9±15	
3.00	 LOW	 96.4±15	 6.4±15	
0.75		 LLOQ	 99.3±20	 12.5±20	
	
Table	2.	Within‐lab	variation/ruggedness	results.	
Prep	 Day	1	CC	(mg/L)	 Day	2	CC	(mg/L)	 Average	 %RSD	
1	 0.96	 0.76	 0.86 8.3±15	
2	 1.13	 1.04	 1.08 3.0±15	
3	 1.42	 1.57	 1.50 3.6±15	
4	 1.20	 1.76	 1.48	 13.4±15	
5	 1.37	 1.35	 1.36	 0.5±15	











Peak	 purity	 index	 and	 the	 similarity	 of	 the	 3	 point	 peak	
purity	 values	 have	 shown	 that	 the	 detected	 peak	 is	 only	
attributed	 to	 CC	 (0.999737	 and	 0.999378,	 respectively).	















Ten	 replicate	 injections	 of	 CC	 solution	 have	 been	
performed	to	check	the	suitability	of	the	HPLC	instrument.	The	
obtained	 RSD%	 ascertained	 that	 the	 HPLC	 system	 was	
working	fine	(8.2%).	Additional	five	replicate	 injections	of	CC	
standard	solution	have	been	performed	to	check	the	suitability	





The	 peak	 areas	 of	 CC	 were	 linear	 with	 respect	 to	 the	







Accuracy	 and	 precision	 were	 established	 by	 analyzing	
high,	 medium	 and	 low	 concentrations	 of	 QC	 samples	
throughout	 the	 standards	 calibration	 range.	 Intra‐assay	 and	
inter‐assay	 precisions	 were	 <	 15%	 (8.2%	 and	 6.14,	 respect‐
tively),	 and	 the	 mean	 values	 of	 the	 accuracy	 were	 between	











Six	 healthy	 volunteers’	 samples	 (Those	 were	 tested	
previously;	 their	 plasma	 samples	 were	 kept	 for	 less	 than	 8	
days	 in	 the	 refrigerator)	 have	 been	 prepared	 by	 another	
analyst	 in	 an	 alternative	 day	 using	 another	 instrument	
(Shimadzu	LC	2010)	in	another	lab	to	validate	the	precision	of	








Stability	 solutions	 were	 prepared	 by	 storing	 prepared	








Stability	 solutions	 were	 prepared	 by	 storing	 plasma	


















8	Days	 Freezer	(‐10	‐ ‐20°C) 99.6	
	
Table	5.	Healthy	samples	results.	
No	 Gender	 Age CC	(mg/L)		
1	 Male	(Smoker)	 41	 0.73	
2	 Male	 37	 0.88	
3	 Male	 33	 0.48	
4	 Male	(Smoker)	 35 1.77	
5	 Male	(Smoker)	 34 1.87	
6	 Male	 57 1.12	
7	 Male	 57 1.71	
8	 Female	 12 0.76	
9	 Female	 42 0.72	
10	 Male	 19 1.37	
11	 Male	 20	 1.19	
12	 Male	 23	 0.96	
13	 Male	 8 1.42	
14	 Male	 16	 1.13	
15	 Male	 43	 1.08	
16	 Female	 58 1.18	















[5].	Mean	and	 range	are	0.96,	0.57‐1.79	mg/L	of	 CC,	 respect‐
tively.	The	obtained	 results	by	our	method;	mean	and	 range:	
1.11,	0.47‐1.87	mg/L	of	CC,	respectively	(Figure	3,	Table	5).	CC	
concentration	 in	 the	 blood	 of	 the	 kidney	 failure	 patients	 has	














utilizing	 their	 PENIA	 method.	 A	 significant	 difference	 was	
observed	 between	 HPLC	 and	 PENIA	 methods,	 in	 which,	 the	
obtained	 means	 were	 3.01	 mg/L	 vs	 6.91	 mg/L	 of	 CC,	











The	 observed	 decay	 behavior	 could	 be	 ascribed	 to	 the	
effect	of	acidic	pH	value	of	 the	used	solvent	(0.05	%	TFA)	on	
CC	[21].	In	addition,	the	freeze/thaw	cycles	have	a	direct	role	
in	 the	 surface‐induced	 denaturation	 phenomenon	 which	
affects	the	proteins	[22].	Interestingly,	the	same	behavior	was	
also	 noticed	 for	 the	 stability	 of	 CC	 in	 the	 urine	 matrix	 at	 a	







No	 Gender	 Age	 Creatinine	(mg/dL)	 CC	(mg/L)	 eGFR	CC	*		 Stage	
1	 Male	 25	 2.89 4.39 12.56	 5	
2	 Male	 84	 2.25 4.41 9.86	 5	
3	 Male	 28	 6.55	 5.71	 8.74	 5	
4	 Male	 22	 4.80	 5.97	 8.44	 5	
5	 Female	 50	 2.59	 5.81	 0.28	 5	
6	 Male	before	dialysis	 31	 2.66	 3.34	 17.58	 4	
7	 Male	after	dialysis	 31	 2.66 2.00 34.71	 3	
8	 Male	 32	 3.30 8.48 5.09	 5	
9	 Female	before	dialysis	 77	 1.95 6.01 0.04	 5	
10	 Female	after	dialysis	 77	 1.95 3.81 0.07	 5	
11	 Female	 49	 3.65 4.88 0.38	 5	
12	 Female	 23	 2.70 3.23 4.12	 5	
13	 Female	 51	 3.16 3.40 0.54	 5	
14	 Female	 74	 1.96	 2.72	 0.14	 5	
15	 Female	 56	 2.53	 2.93	 0.46	 5	
16	 Male	 85	 4.21 2.46 21.28	 4	
17	 Male	 45	 6.51	 2.74	 21.64	 4	
18	 Male	 68	 1.92 2.61 21.05	 4	
19	 Male	 49	 5.78 2.55 23.42	 4	
20	 Male	 24	 5.90 2.72 23.78	 4	
21	 Male	 44	 6.83 3.37 16.55	 4	
22	 Female	 76	 2.70 2.93 0.11	 5	
23	 Female	 13	 4.56 5.23 4.40	 5	
24	 Female	 55	 1.83	 4.43	 0.28	 5	
25	 Female	 47	 3.44 5.16 0.41	 5	
26	 Male	 52	 1.50	 2.64	 22.07	 4	
27	 Female	 51	 1.46	 3.39	 0.54	 5	
Min	 13	 1.46 2.00 0.04	 	
Max	 85	 6.83 8.48 34.71	




















in	 plasma	 up	 to	 one	 72	 hours	 at	 room	 temperature	 [23],	
whereas,	 another	 study	 has	 proved	 the	 stability	 of	 CC	 in	
plasma	 for	 one	 week	 at	 room	 temperature	 [11].	 One	 more	
stability	 study	 showed	 that	 CC	 is	 stable	 for	 26	 days	 at	 room	
temperature;	 the	 current	 stability	 study	 showed	 that	 CC	 is	
stable	 for	 8	 days	 in	 plasma	 at	 the	mentioned	 storage	 condi‐
tions.	 This	 stability	 sounds	 magnificent	 for	 the	 therapeutic	
research	 facilities,	 as	 efforts	 and	 expenses	 can	 be	 both	





Some	of	 the	 studies	have	 reported	 that	 the	production	of	
CC	 is	 not	 influenced	 by	 inflammation	 or	 any	 other	 non‐renal	
factors	 [13],	while	 the	others	have	 reported	 the	 inverse	 [24].	











have	 been	 established	 using	 the	 eGFR	 CC	 equation	 stated	 by	




in	some	cases,	 there	might	be	no	major	 contrasts	 in	 the	 final	
eGFR	 values	 [26,27].	 To	 challenge	 the	 hypothesis	 that	 consi‐
ders	CC	is	eliminated	by	filtration	in	the	dialysis	process	[28],	
pathological	samples	have	been	analyzed	before	and	after	the	
dialysis	 process	 and	 the	 outcomes	 were	 in	 accordance	 with	
that	 hypothesis,	 taking	 into	 consideration	 that	 the	 new	
concentration	 of	 CC	 after	 the	 dialysis	 process	depends	 on	 its	
initial	value,	this	means	that	the	CC	amount	might	return	to	fall	
within	the	healthy	range	(sample	6	and	7,	3.34	and	2.00	mg/L	
of	 CC,	 respectively)	 and	might	 continue	 to	 fall	 in	 the	 patho‐






could	 be	 ascribed	 to	 the	 interferences	 that	 immunoassays	
methods	suffer	 from	(whether	 that	alter	 the	concentration	of	
the	 analyte	 in	 the	 sample	 and/or	 that	 alter	 the	 antibody	
binding).	Despite	that	fact	that,	in	the	nephelometric	methods	
the	interference	is	reduced	by	dilution,	but	it	is	still	observed.	
Furthermore,	 one	 of	 the	 obtained	 results	 using	 the	 PENIA	
method	was	out	of	their	linear	range	(sample	4,	9.59	mg/L	of	
CC),	 in	which,	their	assay	covers	the	range	of	0.23‐7.25	or	8.0	
mg/L	 of	 CC	 [5,29,30].	 Accentuation	 on	 using	 controls	 and	




a	 problematic	 prerequisite	 of	 such	 techniques,	 otherwise,	
unreliable	 results	 are	 highly	 expected	 [31].	 The	 controls	
and/or	 the	 calibrators	 of	 PENIA	 method	 might	 be	 income‐
patible	with	the	submitted	samples	(due	to	different	subjects’	




role	 to	 a	 certain	 extent	 in	 the	 results	 discrepancies	 is	 the	








New	 HPLC	 analytical	 method	 has	 been	 developed	 and	
validated	to	be	utilized	for	healthy	and	unhealthy	population.	
Particularly,	 it	 can	 be	 utilized	 as	 a	 diagnostic	 tool	 for	 the	
susceptible	kidney	 failure	patients	 in	 light	of	 the	obtained	CC	
amounts	in	their	blood	plasma;	therefore,	corrective	action	can	
be	 in	 place	 at	 an	 early	 stage.	 Selectivity	 and	 specificity	 tests	
allow	analyzing	samples	from	different	population	of	different	
zones	 and	 regions	 without	 being	 worried	 about	 getting	
unreliable	 results.	 The	 application	 of	 the	 developed	 HPLC	
method	 can	 be	 extended	 to	 quantify	 CC	 in	 other	 biological	
matrices	 (saliva,	 tears,	 breast	 milk…	 etc.).	 It	 is	 worth	 men‐
tioning,	that	the	assessment	of	pathological	situation	based	on	
the	obtained	CC	levels	in	the	urine	sample	is	much	clearer	than	
the	 analogous	 in	 the	 blood	 sample,	 which	 is	 ascribed	 to	 the	
dramatic	 increase	 of	 CC	 levels	 in	 the	 urine	 in	 case	 of	 kidney	
dysfunction	(200	folds	and	more),	whereas	the	increase	in	the	
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